The company said the draw down is to provide working capital to use on a temporary basis.
The London-based firm plans to fund development and clinical trials for its point-of-care diagnostic test for serious blood infections.
The company replaced an existing $2.5 billion facility with an amended and restated $4 billion facility and entered into a new $7 billion facility.
The firm used about $1.68 billion of proceeds from the new term loans to repay existing secured credit facilities and transaction expenses.
The aggregate commitments for a credit facility reached in September was previously $400 million.
Along with the increase in the amount of the credit facility, its maturity was extended by more than two years to April 1, 2019.
The company's CFO said the agreement reduces Hologic's interest expense, increases its financial flexibility, and extends its debt maturities.
The company has amended and restated a credit facility and a secured revolving note to increase the available borrowing amount for each to up to $120 million.
The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.
The company borrowed $2 million pursuant to an amendment to a $12 million credit agreement. It also said that it has until June 19 to meet certain listing requirements.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.